tradingkey.logo

Eton Pharmaceuticals Inc

ETON
查看詳細走勢圖
23.240USD
-0.210-0.90%
收盤 03/27, 16:00美東報價延遲15分鐘
379.24M總市值
虧損本益比TTM

Eton Pharmaceuticals Inc

23.240
-0.210-0.90%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-0.90%

5天

+4.12%

1月

+36.79%

6月

+9.26%

今年開始到現在

+37.43%

1年

+78.49%

查看詳細走勢圖

TradingKey Eton Pharmaceuticals Inc股票評分

單位: USD 更新時間: 2026-03-27

操作建議

Eton Pharmaceuticals Inc當前公司基本面數據相對非常健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在藥品行業排名33/157位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為37.67。中期看,股價處於上升通道。近一個月,市場表現很強,技術面和基本面綜合得分較高,很強的走勢得到基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Eton Pharmaceuticals Inc評分

相關信息

行業排名
33 / 157
全市場排名
106 / 4542
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Eton Pharmaceuticals Inc亮點

亮點風險
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
業績高增長
公司營業收入穩步增長,連續3年增長152.67%
業績增長期
公司處於發展階段,最新年度總收入79.95M美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入79.95M美元
估值低估
公司最新PE估值-135.91,處於3年歷史低位
機構減倉
最新機構持股16.82M股,環比減少0.00%
景順投資公司持倉
明星投資者景順投資公司持倉,最新持倉6.29K股
活躍度降低
近期活躍度降低,過去20天平均換手率0.64

分析師目標

基於 3 分析師
買入
評級
37.667
目標均價
+60.63%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Eton Pharmaceuticals Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Eton Pharmaceuticals Inc簡介

Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
公司代碼ETON
公司Eton Pharmaceuticals Inc
CEOBrynjelsen (Sean E)
網址https://etonpharma.com/
KeyAI